Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.

Sarepta Therapeutics (SRPT) shares plummeted over 8% Wednesday, extending a year-to-date decline exceeding 84%, following an FDA investigation into two patient deaths linked to its key gene therapy, Elevidys. The deaths, attributed to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients, pose significant regulatory risk, exacerbated by the new FDA head's previous criticism of Elevidys. Analysts warn the FDA could potentially withdraw the therapy for non-ambulatory patients, impacting approximately 50% of the DMD market and Sarepta's projected $1.21 billion in Elevidys sales, which represent over half of the company's expected total revenue this year.

Analysis

Sarepta Therapeutics (SRPT) is facing a severe crisis driven by a new Food and Drug Administration (FDA) investigation into its key gene therapy, Elevidys. The investigation follows the deaths of two non-ambulatory teenage patients from acute liver failure, triggering an over 8% single-day stock decline and extending its year-to-date loss to more than 84%. This regulatory overhang is amplified by a significant leadership change at the FDA's Center for Biologics Evaluation and Research; the new head, Vinay Prasad, is a known critic of Elevidys, increasing the probability of adverse regulatory action. The financial stakes are substantial, as Elevidys is projected to generate $1.21 billion, or 52% of the company's $2.31 billion in expected total sales this year. An analyst from Leerink Partners highlighted the tangible risk that the FDA could revoke approval for non-ambulatory patients, a segment representing approximately 50% of the Duchenne muscular dystrophy market. The extreme negative sentiment is reflected in the stock's technicals, with an IBD Relative Strength Rating of 1, indicating it has performed in the bottom 1% of all stocks over the past year.

Key Decisions for Investors

• Investors should treat any position in Sarepta as highly speculative, given the significant risk that the FDA investigation could lead to a partial or complete market withdrawal of its primary revenue driver, Elevidys.
• Monitor all forthcoming communications from the FDA closely, as any announcement regarding further regulatory action will serve as the primary catalyst for the stock's direction.
• Given the potential for a 50% reduction in Elevidys' addressable market, re-evaluate exposure and consider the severe downside risk until there is definitive clarity on the drug's approved indications and long-term safety profile.